Related Experiment Video
Updated: Jan 8, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Redox-dependent protein S-glutathionylation governs azacitidine sensitivity and resistance in AML
Dušan Nemes1, Michaela Myšáková1, Lubomír Minařík2
1BIOCEV, First Faculty of Medicine, Charles University, Vestec, 25250, Czech Republic; Faculty of Science, Charles University, Prague, 128 00, Czech Republic.
Abstract:
Disruption of redox metabolism is a hallmark of drug-resistant cancer cells, representing a major obstacle to the effective treatment of acute myeloid leukemia (AML). While recent studies have highlighted the importance of redox balance in AML therapy, the specific contribution of protein redox signaling to resistance remains poorly understood. Defining these mechanisms could uncover therapeutic vulnerabilities of resistant AML cells and guide the development of novel combination strategies. Here, we performed comprehensive mass spectrometry-based redox and quantitative proteomic profiling of AML cell lines and patient samples sensitive or resistant to the hypomethylating agent azacitidine (AZA). We demonstrate that AZA disrupts redox homeostasis, which inactivates the glyoxalase system and DNA damage response, and thereby induces cell death. In contrast, AZA resistance is associated with a redox reset characterized by elevated glutathione levels and diminished protein S-glutathionylation. Importantly, AZA failed to induce oxidation of proteins in these pathways in resistant cells and patient-derived AML samples. Pharmacological inhibition of glutathione synthesis restored protein S-glutathionylation and resensitized resistant AML cells to AZA.
Insights
Drug resistance in acute myeloid leukemia (AML) involves altered redox metabolism. Restoring protein S-glutathionylation sensitizes resistant AML cells to azacitidine therapy.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Disrupted redox metabolism is characteristic of drug-resistant cancers, particularly acute myeloid leukemia (AML).
- Understanding protein redox signaling in AML drug resistance is crucial for developing effective therapies.
- Azacitidine (AZA) is a hypomethylating agent used in AML treatment, but resistance limits its efficacy.
Purpose of the Study:
- To investigate the role of protein redox signaling in azacitidine (AZA) resistance in acute myeloid leukemia (AML).
- To identify mechanisms underlying redox homeostasis disruption and restoration in AZA-resistant AML.
- To explore therapeutic strategies for overcoming AZA resistance by targeting redox pathways.
Main Methods:
- Comprehensive mass spectrometry-based redox and quantitative proteomic profiling.
- Analysis of AML cell lines and patient samples sensitive or resistant to azacitidine (AZA).
- Assessment of glyoxalase system and DNA damage response pathways.
Main Results:
- Azacitidine (AZA) disrupts redox homeostasis, inactivating the glyoxalase system and DNA damage response, leading to cell death in sensitive AML.
- AZA resistance is linked to a redox reset with elevated glutathione and reduced protein S-glutathionylation.
- AZA failed to induce protein oxidation in key pathways in resistant AML cells and patient samples.
- Pharmacological inhibition of glutathione synthesis restored protein S-glutathionylation and AZA sensitivity in resistant AML cells.
Conclusions:
- AZA resistance in AML involves a failure to disrupt redox homeostasis, characterized by elevated glutathione levels.
- Targeting glutathione synthesis can restore protein S-glutathionylation and overcome AZA resistance in AML.
- These findings highlight redox signaling as a therapeutic vulnerability in AZA-resistant AML.
More Related Videos
Related Concept Videos
Sulfur Assimilation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Treatment Resistant Cancers
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...

